New Immunotherapy Combination Improves Survival in Metastatic Lung Cancer by 63%
Nowadays the current standard immunotherapy treatment has a survival progression of 7.7 months, while in the GECP study, it reached 13 months. The Spanish Lung Cancer Group (GECP), for its initials in Spanish “Grupo Español de Cáncer de Pulmón”, has verified that a new combination of immunotherapy improves the survival of patients with advanced metastatic lung cancer by 63% and whose results have just been published in the journal ‘JAMA Oncology’.
The GECP study, called ‘Telma’, selected patients with advanced metastatic lung cancer who were candidates for immunotherapy and who, in addition, could be given a new pharmacological combination by adding anti-angiogenic that would enhance the action of immunotherapy.
In this sense, the president of the GECP and lead author of the study, Dr. Mariano Provencio, explains “currently we select patients who are candidates for immunotherapy based on whether they have a high expression of the PDL1 gene. This limits us since only between 20% and 30% of these patients have that gene”.
According to those mentioned above, with the new approach proposed by the ‘Telma’ study, the GECP researchers believe that more patients will benefit from immunotherapy.
The data on response to treatment and survival from the ‘Telma” study improve the current standard. “We have verified that the combination of ‘atezolizumab’ with ‘bevacizumab’ as the first line of treatment in patients with advanced lung cancer and high mutational load increases survival rates, with long-lasting responses to treatment and a favorable safety and toxicity profile”, details the expert.
Thus, with the current standard treatment, progression-free survival is 7.7 months, while in the GECP study, 13 months are reached, 63% more. In addition, 72% of the patients participating in the study survived during the first year.
Therefore, Dr. Provencio highlights that “the findings suggest that this new approach could be added to the potential treatments for this population group. Obviously, it is a phase II academic study and should lead to additional studies to confirm it.”
With this study, the Spanish GECP researchers provide information on a new way of selecting patients with metastatic lung cancer for monotherapy (without chemotherapy) and a new treatment combination.
SERVIMEDIA. (2022, 16th December). Una nueva combinación de inmunoterapia
mejora un 63% la supervivencia en el cáncer de pulmón metastásico. ELMUNDO. https://www.elmundo.es/ciencia-y salud/salud/2022/12/16/639c666cfc6c8304778b45c3.html